Healthcare Providers and Services
Company Overview of The Cleveland Clinic Foundation
The Cleveland Clinic Foundation, doing business as Cleveland Clinic Health System, is a foundation that owns and operates hospitals and healthcare centers and provides clinical and hospital care, research, and educational services. The group treats different illness and disorders including anesthesia, brain tumor, cancer, cardiovascular, arthritis, blood, diabetes, infertility, kidney, skin, rehabilitation, hernia, central nervous system, endocrinology, and genetics. The institution was founded in 1921 and is based in Cleveland, Ohio.
9500 Euclid Avenue
Cleveland, OH 44195
Founded in 1921
Key Executives for The Cleveland Clinic Foundation
Chief Executive Officer, President, Director, and Chairman of the Board of Governors
Chief Financial Officer and Treasurer
Chairman of Taussig Cancer Institute, Vice Chairman, Chief of Staff Office, and Executive Director of Strategic Space
Chief Marketing, Planning, and Communications Officer
Compensation as of Fiscal Year 2016.
The Cleveland Clinic Foundation Key Developments
The Cleveland Clinic Foundation Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 01:30 PM
Jan 6 17
The Cleveland Clinic Foundation Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 01:30 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Steven C. Glass, Chief Financial Officer and Treasurer.
Cleveland Clinic Announces Management Changes
Sep 21 16
Cleveland Clinic has appointed Michael Steinmetz, M.D., as chairman of its Department of Neurosurgery. In this role, Dr. Steinmetz will lead a team of neurosurgeons devoted to the most advanced surgical treatments for patients with neurological disorders and injuries. In addition to his clinical role, Dr. Steinmetz will oversee the administrative and academic activities of the Department of Neurosurgery, while continuing to serve in a leadership role in The Center for Spine Health. He serves as the vice president of the Congress of Neurological Surgeons, secretary of the Council of State Neurological Societies, an executive committee member of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, and involved with the American Association of Neurological Surgeons, the North American Spine Society and the Society for Neurosciences. He is on the board of directors of the NeuroPoint Alliance. Dr. Steinmetz replaces Edward Benzel, M.D., who stepped down as neurosurgery chair. Dr. Benzel will work closely with Dr. Machado as the director for patient experience and staff career development, along with his very busy clinical practice.
Cleveland Clinic, UCLA and University of California San Diego Collaboration Demonstrates Potential Treatment Enhancement for Advanced Brain Cancer
Jun 1 16
Doctors at Cleveland Clinic, UCLA, University of California San Diego School of Medicine and additional institutions have achieved a milestone in development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with recurrent glioblastoma. Glioblastomas are the most deadly of all brain cancers. If the tumor recurs following chemotherapy and radiation, there are very few treatment options left, and patients have only months to live. In a phase I multi-center clinical trial, Cloughesy and Vogelbaum afound that, of the 43 participants who were given the investigational treatment Toca 511 and Toca FC, overall survival increased to 13.6 months compared to 7.1 months for an external control. For some patients, survival was extended to more than two years with few side effects. In 2016, the total number of newly diagnosed high-grade glioblastoma will be about 160,000 worldwide, including 14,000 in the United States. The new findings were led by Drs. Timothy Cloughesy, a member of the UCLA Jonsson Comprehensive Cancer Center and director of the UCLA neuro-oncology program, and Michael A. Vogelbaum, professor of neurosurgery and associate director of the brain tumor neuro-oncology center at the Cleveland Clinic. Their work is the first publication of clinical data involving this new type of modified virus known as a retroviral replicating vector (RRV). RRVs can deliver a gene with a specific function to a cancer cell, and insert it, thereby debilitating the cell. The use of RRVs shows tremendous promise in the development of innovative new therapies for all types of brain cancer. During the first step of treatment the patient is given an injection of Toca 511, which is a modified virus that selectively infects actively dividing cancer cells and delivers a gene for an enzyme called cytosine deaminase (CD) to the cancer cells. As it spreads through the tumor, Toca 511 programs the cancer cells to make (CD). Once they do, the cancer cells are then ready for the second step of the treatment. Next, the patient is prescribed oral cycles of Toca FC, an antifungal drug, for seven days, every four to eight weeks. The genetic changes created by Toca 511 allows infected cancer cells to convert Toca FC into the FDA-approved anticancer drug, 5-fluorouracil (5-FU). As a result, infected cancer cells and immunosuppressive cells are selectively killed, subsequently activating the immune system to recognize and kill cancer cells, while leaving healthy cells unharmed. In other words, the therapies work together to attack brain cancer cells from the inside. An estimated 40% of study participants who received higher doses of the combo treatment during the phase I clinical trial were still living after two years. The researchers also noted that some study participants had partial or complete shrinkage of their tumor. Importantly, Toca 511 & Toca FC demonstrated a favorable safety and tolerability profile.
Similar Private Companies By Industry
Recent Private Companies Transactions